NCT06465329 2026-02-12
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Regeneron Pharmaceuticals
Phase 2 Recruiting
Regeneron Pharmaceuticals
Weill Medical College of Cornell University
Rutgers, The State University of New Jersey
Lithuanian University of Health Sciences
Incyte Corporation
New Mexico Cancer Research Alliance
West Japan Thoracic Oncology Group